8-K: TOMI Environmental Solutions Reports Mixed 2023 Results Amidst Expansion Efforts

TOMI Environmental Solutions reported a decrease in revenue and increased net losses for 2023, despite expanding its sales infrastructure and product line.

Summary

• TOMI Environmental Solutions announced its financial results for the fourth quarter and year ended December 31, 2023.
• Total net revenue for 2023 was $7.355 million, a decrease from $8.338 million in 2022.
• The company's gross margin decreased to 58.3% from 60.6% due to product mix changes.
• Operating loss for the year was $3.349 million, compared to $2.882 million in the previous year.
• Net loss for 2023 was $3.403 million, or $0.17 per share, compared to a net loss of $2.880 million, or $0.15 per share in 2022.
• For the fourth quarter of 2023, total net revenue was $1.528 million, down from $2.812 million in the same period of 2022.
• The fourth quarter gross margin was 54.9%, compared to 58.6% in the prior year.
• The operating loss for the fourth quarter was $1.171 million, compared to $706,000 in 2022.
• Net loss for the fourth quarter was $1.226 million, or $0.06 per share, compared to a net loss of $705,000, or $0.04 per share in 2022.
• Cash and cash equivalents were approximately $2.3 million as of December 31, 2023.
• Working capital was $7.9 million and shareholders' equity was $8.4 million as of the end of 2023.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to decreased revenue and increased losses, although there are positive developments in sales infrastructure and product expansion. The company is showing growth in some areas but the overall financial results are concerning.

Positives

• The company expanded its sales infrastructure significantly in 2023.
• TOMI secured a contract with Vizient, a large healthcare purchasing organization.
• SteraMist iHP service revenue grew by 13% year-over-year.
• The company successfully delivered four custom engineered systems.
• TOMI introduced three new products to diversify its offerings.
• The company has a growing list of premium clients in various sectors.
• The company has seen further growth in its iHP service revenue in early 2024.

Negatives

• Total net revenue decreased to $7.355 million in 2023 from $8.338 million in 2022.
• Gross margin decreased to 58.3% in 2023 from 60.6% in 2022.
• Operating loss increased to $3.349 million in 2023 from $2.882 million in 2022.
• Net loss increased to $3.403 million in 2023 from $2.880 million in 2022.
• Fourth quarter revenue decreased to $1.528 million from $2.812 million in the same period of 2022.
• The company experienced a decrease in gross profit due to product mix.
• The timing of orders and lengthy customer approval processes affected revenue.

Risks

• The company's ability to acquire new customers and expand sales is a risk.
• Maintaining and managing growth and generating sales is a challenge.
• TOMI relies on a single or a few products for a majority of its revenues.
• General business and economic conditions could impact the company.
• The company's products have long sales cycles which can impact revenue recognition.

Future Outlook

The company anticipates that the increased bandwidth of its sales channels will positively impact revenue in 2024 and beyond, and that new products will be the primary driver of growth in the coming years. They expect to drive revenue growth over the next 18 months as the number of engagements grows.

Management Comments

• During 2023 we continued to expand our sales infrastructure through the broadening of our distribution network, diversify our product line to support our growing customer base and the related utilization of our SteraMist technology and deliver multiple custom engineered systems to key customers.
• We remain focused on expanding our internal and external sales infrastructure and business development initiatives.
• We anticipate the increased bandwidth of our internal and external sales channels will have a positive impact on our revenue in 2024 and beyond.
• These new products will be the primary driver of growth in the years to come.
• We are off to a good start in 2024 as we landed a new SteraMist iHP Custom Engineered System (CES) installation with a California-based life sciences company and have seen further growth in our iHP service revenue.
• We will continue to focus on executing our strategies to grow revenues, expand business development and deliver improved results and value for our shareholders.

Industry Context

The company operates in the disinfection and decontamination sector, which has seen increased attention due to health and safety concerns. The expansion of their sales network and product line is aimed at capturing a larger share of this growing market. The partnership with Vizient is a strategic move to increase their presence in the healthcare sector.

Comparison to Industry Standards

• While TOMI's revenue decreased year-over-year, companies like Steris and Ecolab, which are larger players in the infection prevention and hygiene space, have shown more consistent revenue growth. However, these companies have a broader range of products and services.
• TOMI's gross margin of 58.3% is within the range of other companies in the specialty chemicals and environmental services sector, but it is lower than some of the larger players.
• The company's operating and net losses are a concern, especially when compared to more established companies in the industry that are profitable.
• The growth in SteraMist iHP service revenue is a positive sign, indicating a demand for their specialized services, which is a key differentiator compared to companies that primarily sell products.

Stakeholder Impact

• Shareholders will be concerned about the decreased revenue and increased losses.
• Employees may be impacted by the company's financial performance.
• Customers may benefit from the expanded product line and services.
• Suppliers may be affected by the company's financial situation.
• Creditors may be concerned about the company's increased losses.

Next Steps

• The company will continue to focus on executing its strategies to grow revenues.
• They will expand business development initiatives.
• They will deliver improved results and value for shareholders.
• The company will focus on the upcoming launch of new products.

Key Dates

Keywords

disinfection, decontamination, SteraMist, Binary Ionization Technology, iHP, healthcare, pharmaceutical, revenue, financial results, sales, custom engineered systems